Scimega, Canada’s Premier CRO, Introduces Julie Martin, CEO
Julie Martin, MSc, MBA, Lean certified, CEO and Co-owner has been part of the team at Scimega, since 2013. Her…
Overcome Oncology Clinical Trial Obstacles – 2020 Real World Evidence for 2021 and Beyond
Study start-up is one the most time-intensive areas within clinical drug development, accounting for two thirds or more of total…
Continued Importance of CRAs Supporting Role for Patient Centric Trials
The COVID-19 world-wide pandemic has forced the clinical trial industry to make rapid changes in order to continue protecting participant…
Some Facts About Canada… Mitigate COVID-19 Impact on Your Clinical Trials
People often adhere to a myth and perpetuate it in answer to a difficult question, ending all further inquiry into…
Smaller CROs May Do It Better, Quicker – Especially in Times of Crisis
Pursuit of a path from discovery to drug approval as quickly as possible is a clear objective for most biotech…
Consider This Region for Your Phase 3 Global Trial
As of May 2020 ClinicalTrials.gov lists 16,150 oncology trials registered as Recruiting, Not yet Recruiting Studies, and the chart below…
Recommendations for Quicker CTA Negotiation
Whether in Canada or any other country it is no secret that executing Clinical Trial Agreements (CTAs) is often the…
Overcome Today’s New Enrollment Challenges
Choose Your Specialized CRO Partner Well The global clinical trials market is expected to reach $69.8 billion US by 2027,…
CRAs Play a Supporting Role in Patient-Centric Trials
There is an ever-present desire in the clinical trial industry to practice ‘patient-centricity’. This practice is featured predominantly during the…
Collaborative Vendor Teaming for Better Oncology Trial Results – Real World Evidence
Workplace collaboration requires a willingness to find solutions to problems, together with others. Which means that any successful collaborative vendor…